Products Affected - Description

• • Nexterone injection, Baxter, 150 mg/100 mL, premixed bag, 12 count, NDC 43066-0150-10
  • Nexterone injection, Baxter, 360 mg/200 mL, premixed bag, 10 count, NDC 43066-0360-20
  • Amiodarone injection, Fresenius Kabi, 50 mg/mL, 3 mL vial, 10 count, NDC 63323-0616-03
  • Amiodarone injection, Hikma, 50 mg/mL, 3 mL vial, 25 count, NDC 00143-9875-25

Reason for the Shortage

• • AuroMedics discontinued amiodarone in mid-2021.
  • Baxter has Nexterone premixed bags on shortage due to manufacturing delays.
  • Fresenius Kabi did not provide a reason for the shortage.
  • Hikma did not provide a reason for the shortage.
  • Viatris did not provide a reason for the shortage.
  • Sagent discontinued amiodarone 50 mg/mL 3 mL syringes in June 2019.

Available Products

• • Amiodarone injection, Fresenius Kabi, 50 mg/mL, 9 mL vial, 10 count, NDC 63323-0616-09
  • Amiodarone injection, Mylan Institutional (Viatris), 50 mg/mL, 18 mL vial, 10 count, NDC 67457-0153-18
  • Amiodarone injection, Mylan Institutional (Viatris), 50 mg/mL, 3 mL vial, 10 count, NDC 67457-0153-03
  • Amiodarone injection, Mylan Institutional (Viatris), 50 mg/mL, 9 mL vial, 10 count, NDC 67457-0153-09

• • Fresenius Kabi has amiodarone 50 mg/mL 3 mL vials on back order and the company cannot estimate a release date.
  • Hikma has amiodarone 50 mg/mL 3 mL vials on allocation.
  • Baxter has Nexterone 150 mg/100 mL premixes and 360 mg/200 mL premixes on allocation.